Ethyl Acetate → 3-(4-(1-(2,2-Dimethyl-1,3-dioxolan-4(S)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)-5(R)-(N-(t-butoxycarbonyl)pyridazin-3ylaminomethyl)oxazolidin-2-one

HRID 8182

Reaktionsgleichung

Reaktionsgleichung von HRID 8182
[OH:1][C@@H:2]([CH2:33][OH:34])[C:3]([N:5]1[CH2:10][CH2:9][C:8]([C:11]2[C:16]([F:17])=[CH:15][C:14]([N:18]3[CH2:22][C@H:21]([CH2:23]NC4C=NC=CN=4)[O:20][C:19]3=[O:31])=[CH:13][C:12]=2[F:32])=[CH:7][CH2:6]1)=[O:4].[C:35]([O:39][C:40]([NH:42][C:43]1[N:44]=[N:45][CH:46]=[CH:47][CH:48]=1)=[O:41])([CH3:38])([CH3:37])[CH3:36].N1[CH:54]=[CH:53]N=CC=1.[C:55](OCC)(=O)C>ClCCl>[CH3:55][C:53]1([CH3:54])[O:1][C@H:2]([C:3]([N:5]2[CH2:10][CH2:9][C:8]([C:11]3[C:12]([F:32])=[CH:13][C:14]([N:18]4[CH2:22][C@H:21]([CH2:23][N:42]([C:43]5[N:44]=[N:45][CH:46]=[CH:47][CH:48]=5)[C:40]([O:39][C:35]([CH3:38])([CH3:36])[CH3:37])=[O:41])[O:20][C:19]4=[O:31])=[CH:15][C:16]=3[F:17])=[CH:7][CH2:6]2)=[O:4])[CH2:33][O:34]1

Komponenten

6

Versuchsvorschrift

Essentially the technique for the appropriate intermediate of Example 22 was used, but substituting 3-(t-butoxycarbonylamino)pyridazine (293 mg, 1.5 mM) for the pyrazine analogue. The reaction was carried out by heating at 45° for 4 hour, and the chromatography was carried out with a gradient from 0% to 100% ethyl acetate in dichloromethane. Relevant fractions were combined to give the desired product (315 mg).

Aufarbeitung

  1. temperatureby heating at 45° for 4 hour

Quellen und Nachweise

ORD-Eintrag
ord-c6b7e39aa88a417b83bfa4edaf24c448
Quelldatensatz
uspto-grants-2006_08
Patentnummer
US07087629B2

Verknüpfte Notizen

Wird geladen…